Healius Ltd
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patie… Read more
Market Cap & Net Worth: Healius Ltd (HLS)
Healius Ltd (AU:HLS) has a market capitalization of $265.27 Million (AU$428.42 Million) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #14816 globally and #196 in its home market, demonstrating a -3.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Healius Ltd's stock price AU$0.59 by its total outstanding shares 726133000 (726.13 Million).
Healius Ltd Market Cap History: 2015 to 2026
Healius Ltd's market capitalization history from 2015 to 2026. Data shows change from $768.66 Million to $265.27 Million (-14.03% CAGR).
Index Memberships
Healius Ltd is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$457.28 Billion | 0.05% | #116 of 495 |
|
S&P/ASX All Australian 200
AXAT
|
$418.41 Billion | 0.05% | #75 of 200 |
|
S&P/ASX 200
AXJO
|
$404.15 Billion | 0.05% | #60 of 200 |
|
S&P/ASX 200 Accumulated
AXJOA
|
$404.15 Billion | 0.05% | #60 of 200 |
|
S&P/ASX 300
AXKO
|
$548.39 Billion | 0.04% | #112 of 300 |
|
ASX Small Ordinaries
AXSO
|
$70.56 Billion | 0.30% | #81 of 200 |
Weight: Healius Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Healius Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Healius Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.30x
Healius Ltd's market cap is 0.30 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $1.61 Billion | $38.40 Million | 0.86x | 35.99x |
| 2017 | $1.27 Billion | $1.66 Billion | -$516.80 Million | 0.76x | N/A |
| 2018 | $835.78 Million | $1.74 Billion | $4.10 Million | 0.48x | 203.85x |
| 2019 | $1.06 Billion | $1.57 Billion | $55.30 Million | 0.68x | 19.18x |
| 2020 | $1.45 Billion | $1.58 Billion | -$70.50 Million | 0.91x | N/A |
| 2021 | $2.11 Billion | $1.90 Billion | $43.70 Million | 1.11x | 48.34x |
| 2022 | $1.28 Billion | $2.29 Billion | $307.90 Million | 0.56x | 4.15x |
| 2023 | $735.12 Million | $1.71 Billion | -$367.80 Million | 0.43x | N/A |
| 2024 | $615.97 Million | $1.75 Billion | -$645.80 Million | 0.35x | N/A |
| 2025 | $406.90 Million | $1.34 Billion | -$151.20 Million | 0.30x | N/A |
Competitor Companies of HLS by Market Capitalization
Companies near Healius Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Healius Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Healius Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Healius Ltd's market cap moved from $768.66 Million to $ 265.27 Million, with a yearly change of -14.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$265.27 Million | -34.81% |
| 2025 | AU$406.90 Million | -33.94% |
| 2024 | AU$615.97 Million | -16.21% |
| 2023 | AU$735.12 Million | -42.46% |
| 2022 | AU$1.28 Billion | -39.53% |
| 2021 | AU$2.11 Billion | +45.80% |
| 2020 | AU$1.45 Billion | +36.64% |
| 2019 | AU$1.06 Billion | +26.88% |
| 2018 | AU$835.78 Million | -33.96% |
| 2017 | AU$1.27 Billion | -8.43% |
| 2016 | AU$1.38 Billion | +79.78% |
| 2015 | AU$768.66 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Healius Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $265.27 Million USD |
| MoneyControl | $265.27 Million USD |
| MarketWatch | $265.27 Million USD |
| marketcap.company | $265.27 Million USD |
| Reuters | $265.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.